Vtama Alternatives Compared
| Vtama (tapinarof) | Stelara (ustekinumab) | Otezla (apremilast) |
|
|---|
| Vtama (tapinarof) | Stelara (ustekinumab) | Otezla (apremilast) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Atopic Dermatitis, Plaque Psoriasis. Vtama may also be used for purposes not listed in this medication guide. |
Prescription only
Stelara is an immunosuppressant medication that works by binding to two inflammatory cytokines, IL-12 and IL-23, which have been identified as important contributors to chronic inflammation. Stelara... View more |
Prescription only
Otezla is a PDE4 inhibitor that may be used to treat adults with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s Disease. It may also be used to treat plaque psoriasis... View more |
||||||||||||||||||||||||
| More about Vtama (tapinarof) | More about Stelara (ustekinumab) | More about Otezla (apremilast) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Vtama has an average rating of 8.0 out of 10 from a total of 36 ratings on Drugs.com. 77% of reviewers reported a positive effect, while 11% reported a negative effect. |
Stelara has an average rating of 7.7 out of 10 from a total of 251 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 15% reported a negative effect. |
Otezla has an average rating of 5.2 out of 10 from a total of 439 ratings on Drugs.com. 35% of reviewers reported a positive effect, while 40% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Vtama prices |
View all Stelara prices |
View all Otezla prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other ustekinumab brands include: Imuldosa, Otulfi, Pyzchiva, Selarsdi, Steqeyma, Wezlana, Yesintek |
N/A |
||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
1291.2 hours |
9 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
A total of 533 drugs are known to interact with Stelara:
|
A total of 106 drugs are known to interact with Otezla:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
May 23, 2022 |
September 25, 2009 |
March 21, 2014 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.